ArticleJournal of robotic surgery2026
Establishing a sustainable and high-utilization robot-assisted surgery platform in a regional cancer center: insights from a multidisciplinary, break-even-guided operational strategy.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoption of robot-assisted surgery (RAS) in regional non-urban cancer centers is constrained by high fixed costs and insufficient case volumes to achieve financial sustainability. Break-even thresholds vary widely (120-300 cases/year) across institution types; however, operational models for resource-constrained settings remain poorly characterized. To evaluate whether a financially sustainable, high-utilization RAS platform centered on colorectal cancer surgery can be established in a regional, non-urban cancer center through a four-phase, cross-departmental, volume-driven strategy guided by break-even analysis. A single da Vinci Xi system was shared across surgical departments. Annual fixed costs totaled ¥47,500,000, incremental revenue was ¥650,000/case, and variable instrument costs were ¥300,000, ¥350,000, and ¥400,000. A four-phase strategy was implemented: anchoring volume through urology, expanding into colorectal surgery via structured proctorship, broadening colorectal indications, and dynamically allocating robotic capacity across departments. Annual RAS volume reached 254 cases in 2025, exceeding the break-even threshold of 200-250 cases across cost scenarios. Robot-assisted colorectal surgery increased fifteen-fold between April and October 2025, stabilizing at 6-9 cases/month. Weekday utilization reached 1.2-1.5 cases/day in high-volume months and remained at or above 100% throughout the maturation phase. A sensitivity analysis confirmed that procedural volume, not instrument cost variation, is the dominant determinant of financial sustainability. A sustainable, high-utilization RAS platform is achievable within 18-24 months using a four-phase, volume-driven strategy. Under Japan's reimbursement structure, 200-250 annual cases represent the critical break-even threshold. This framework offers a transferable roadmap for non-urban cancer centers facing barriers to adoption.
Indexed as
Identifiers
42627549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.